Key facts
- Calytrix said the transaction includes an upfront payment plus payments tied to clinical trial and regulatory milestones.
- Calytrix did not disclose the size of the upfront payment or the deal's expected closing date.
- Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis.
- The deal is expected to add an experimental hematology treatment to Lilly's portfolio, which includes the FDA-approved Jaypirca.
Eli Lilly agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, Calytrix said on November 16, 2026. The transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones. Calytrix did not disclose the size of the upfront payment or the deal's expected closing date.
Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis, rare blood disorders in which the bone marrow produces excessive abnormal blood cells. The deal is expected to strengthen Lilly's presence in hematology, adding an experimental treatment to a business that already includes Jaypirca, an FDA-approved blood cancer medicine.
The purchase is the latest in a string of acquisitions by the Indianapolis-based company as it works to diversify beyond its diabetes and weight-loss franchise, which the report describes as its primary growth engine.